METHOD FOR CLINICAL AND LABORATORY PREDICTION OF CYTOKINE STORM IN PATIENT DIAGNOSED WITH COVID-19 Russian patent published in 2024 - IPC G01N33/68 G01N33/49 G01N33/566 G01N33/569 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical and laboratory diagnostics, infectious diseases, and can be used for clinical and laboratory prediction of cytokine storm during hospitalization in a patient diagnosed with COVID-19. Virus is identified without signs of cytokine storm at the moment of hospitalization by measuring concentration of signal proteins in patient’s blood serum, obtained before the therapy was prescribed. Concentration of interferon γ induced protein 10 (IP-10), CD40 ligand in soluble form (sCD40L), vascular endothelial growth factor (VEGF) is measured in patient's blood serum. According to one of the obtained criteria: (1) IP-10 from 2,146 to 4,289 pg/ml inclusive; (2) IP-10 more than 6,710 pg/ml; (3) IP-10 from 475 to 1,487 pg/ml inclusive, and sCD40L is less than or equal to 8,029 pg/ml; (4) IP-10 from 475 to 1,487 pg/ml inclusive, and sCD40L is more than 8,029 pg/ml, and VEGF is less than or equal to 66 pg/ml; where: IP-10 – interferon γ induced protein 10; sCD40L is a CD40 ligand in a soluble form; VEGF – vascular endothelial growth factor; pg/ml – picograms per millilitre, developing a cytokine storm in a hospitalized patient is predicted.

EFFECT: method enables to predict with high accuracy the development of a cytokine storm in the patients diagnosed with coronavirus infection COVID-19 before standard clinical and laboratory tests can detect the presence of a cytokine storm by measuring the blood concentration of IP-10, sCD40L and VEGF.

1 cl, 2 dwg, 2 tbl, 5 ex